COVID-19 Severity and Immune Response Tied to Gut Bacteria

Scientists report that gut microorganisms in COVID-19 patients were very different from those in uninfected individuals and lack of good bacteria that regulate our immune system.

The presence of an abnormal gut bacteria persists after the virus is gone and may be responsible of the long-lasting symptoms in some patients. In addition, reduction of inflammation biomarkers in patient’ blood, correlate favorable with good bacteria in their stool and the development of neutralizing antibodies to the virus. (https://gut.bmj.com/content/early/2021/01/04/gutjnl-2020-323020).

Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.

"*" indicates required fields

NAME:*

EMAIL:*

PHONE NUMBER:

COMMENTS:*

CAPTCHA

Comments

This field is for validation purposes and should be left unchanged.